Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has earned an average rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $61.18.

Several equities research analysts recently weighed in on the company. Bank of America upped their price target on Tempus AI from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Loop Capital decreased their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Morgan Stanley boosted their price objective on shares of Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Piper Sandler decreased their target price on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Finally, JPMorgan Chase & Co. cut Tempus AI from an “overweight” rating to a “neutral” rating and boosted their price target for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, major shareholder Bradley A. Keywell sold 265,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the transaction, the insider now owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. This represents a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Wayne A.I. Frederick sold 3,000 shares of Tempus AI stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the sale, the director now owns 26,514 shares of the company’s stock, valued at $1,207,447.56. This represents a 10.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,411,249 shares of company stock worth $310,486,558.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of the company. Operose Advisors LLC purchased a new stake in Tempus AI during the fourth quarter valued at $25,000. Farther Finance Advisors LLC purchased a new stake in shares of Tempus AI during the 4th quarter valued at about $34,000. Prestige Wealth Management Group LLC lifted its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock worth $36,000 after purchasing an additional 965 shares during the period. NewEdge Advisors LLC purchased a new position in shares of Tempus AI in the fourth quarter worth approximately $49,000. Finally, First Horizon Advisors Inc. grew its position in Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after buying an additional 1,108 shares during the period. 24.22% of the stock is owned by institutional investors.

Tempus AI Price Performance

Tempus AI stock opened at $40.86 on Thursday. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The stock’s 50 day simple moving average is $54.66 and its two-hundred day simple moving average is $50.71. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.